• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding

    The Baseline

    12
    Following
    368
    Stocks Tracked
    49
    Sectors & Interests
    Follow
    Load latest
    logo
    The Baseline
    01 Jun 2022
    Chart of the Week: Insiders that cashed in as stock markets peaked

    Chart of the Week: Insiders that cashed in as stock markets peaked

    Before the Indian stock market corrected significantly in April 2022, domestic investors kept pushing theNifty 50 higher after every dip. This upward march allowed someinsiders to offload their stakes in listed companies at high valuations.

    From January 2022 to March 2022, there were significant offloads in five companies by insiders before the market crashed. These insiders include investors who owned stakes in companies that recently went IPO, as well as promoters, directors, and designated persons ('designated persons' are unnamed individuals who are insiders and may have access to price-sensitive information).

    Mathew Cyriac, who had a large stake inMTAR Technologies through private equity firmsFabmohur Advisors LLP andSolidus Advisors LLP, sold 8.9% stake worth Rs 495.3 crore through the firms. Fabmohur Advisors sold a 7.4% stake worth Rs 407.4 crore in the last week of March, while Solidus Advisors sold a 1.6% stake worth Rs 87.9 crore in the last week of March 2022. Cyriac bought his 30% stake in the company forRs 34 crore in 2017, so this was a very profitable sale.

    In FSN E-Commerce Ventures (Nykaa), designated persons sold a total 0.2% stake valued at Rs 178.5 crore between Feb 2022 and March 2022.

    Then comes Vishad P. Mafatlal, promoter ofNavin Fluorine International, who sold a 0.48% stake worth Rs 94.1 crore in the second week of March 2022.

    SBI Life Insurance’s joint venture partner BNP Paribas promoter sold 0.2% stake worth Rs 220 crore in last week of February 2022. However, it looks like the market was already jittery about the impending sale, as the stock crashed in early February before the sale was executed by BNP Paribas.Crompton Greaves Consumer Electricals’ designated persons sold 0.29% stake worth Rs 71.5 crore from February 2022 to early April 2022.

    Now that the markets are choppy, it will be interesting to see the moves insiders make over the rest of the year.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    30 May 2022
    Five analyst picks that outperformed the Nifty 50

    Five analyst picks that outperformed the Nifty 50

    Considering the volatility in the markets, five analyst picks looks at stocks that outperformed the Nifty 50 over the past week and have a buy call from analysts in the past month. 

    1. Bata India: Edelweiss maintains a ‘Buy’ call on this footwear company with a target price of Rs 2,365. This indicates an upside of 26%. The company outperformed the Nifty 50index by 4.1% over the past seven days.

    “Bata India's performance in Q4FY22 was better than expected on the margin front,” say analysts Kapil Jagasia and Praveen Sahay. Gross margin increased 450bps YoY to 57.6% and  EBITDA margins expanded 540bps YoY to 24.4%. According to the analysts, margins improved on account of price hikes, lower discounting and manufacturing efficiencies. In Q4FY22, revenue grew 13% YoY to Rs 665 crore (10% lower than analysts’ estimates) but profit was up 11.3% YoY to Rs 63 crore (25% higher than estimates).

    “The management’s continuous focus on cost control measures, distribution expansion, and cash-rich balance sheet (Rs 1,092 crore as of March 2022) are key positives for the company,” Jagasia and  Sahay said. They further added that Bata’s strong market leadership, revival of formal footwear along with strong growth in casual portfolio and various distribution initiatives, would help it recoup its lost revenue in FY23.

    1. Dr. Reddy's Laboratories: Axis Securities maintains a ‘Buy’ call on this pharmaceuticals company but has reduced the target price to Rs 4,500 from Rs 5,100, now indicating an upside of 3%. The stock outperformed the Nifty 50index by 0.3% over the past seven days. 

    In Q4FY22, the company reported revenue growth of 14.8% YoY (vs the brokerage’s expectation of 8%) to Rs 5,475 crore. Analyst Ankush Mahajan believes that it was “led by strong performance in geographies such as the US, India, and Emerging Markets.” Mahajan adds, “Dr. Reddy is currently investing in various businesses that may provide excellent growth in the long term.” According to him, the company is building a global pipeline of biosimilars, developing a new chemical entity for Immuno-oncology, and building up a neutraceuticals portfolio, vaccines, CDMO (contract development and manufacturing company), and digital healthcare platforms. However, Axis cautions that high inflation could decrease margins.

    1. Container Corporation of India: Motilal Oswal maintains a ‘Buy’ on this warehousing and logistics company but has reduced its target price to Rs 710, indicating an upside of 6.9%. The stock outperformed the Nifty 50 index by 13.4% over the past seven days.

    Analysts Alok Deora and Dhirendra Patro said, “Container Corp reported a weak operational performance in Q4FY22 with margin contracting 20.2% (versus estimate of 23.8%) due to higher provisions made towards employee costs and higher other expenses.” Volumes and revenue were in line with their estimates.  In Q4FY22, the company’s revenue grew 5% YoY to Rs 2,043 crore and total volumes remained flat YoY at 1.07 million twenty-foot equivalent units (TEUs). The analysts note that the company is planning a capex of Rs 8,000 crore over the next 3-4 years to be funded through internal accruals. “We expect volumes to pick up with commissioning of DFCs, thereby leading to 19% revenue CAGR during FY22-24,” they added. They also believe that with the pick-up in domestic volumes, EBITDA margin is likely to be stable at 23%, resulting in a 20% EBITDA CAGR over FY21-24.

    1. Britannia Industries: Geojit BNP Paribas maintains a ‘Buy’ rating on this FMCG company’s stock with a target price of Rs 3,890, indicating an upside of 8.9%. The stock outperformed the Nifty 50 index by 1.1% over the past seven days. 

    Analyst Vincent K.A. is positive about the company’s prospects. He adds, “Britannia has a robust portfolio and efficient distribution network”. In Q4FY22 net profit rose by 4.3% YoY to Rs 380 crore and revenue rose by 15.5% YoY to Rs 3,508.4 crore. The analyst noted revenues rose because of price hikes and an increase in volumes, adding that the number of rural distributors increased 13% YoY to 26,000 in FY22. However, EBITDA margins fell by 90 bps YoY to 15.7% due to input cost inflation in Q4FY22 and Vincent expects inflation in commodity prices to put pressure on margins in the near term. The management is expected to undertake price increases and grammage cuts to offset the pressure on margins. Geojit estimates the company’s profit to grow at a 16.8% CAGR over FY22-24.

    1. Ashok Leyland: LKP Securities maintains a ‘Buy’ rating on this commercial vehicle maker with a target price of Rs 173, indicating an upside of 23.9%. This stock outperformed the Nifty 50 index by 4.4% over the past seven days. 

    Analyst Ashwin Patil said “the company posted a superb set of numbers in Q4 with all the underlying parameters falling in place”. The company’s standalone net profit rose 3.7X YoY to Rs 901.4 crore and revenue 25% YoY to Rs 8,744.3 crore. Patil believes higher realisations were the main drivers of this growth which were up 13% YoY due to price hikes and a better product mix. Patil expects the company to maintain this growth momentum on pick up in CV (commercial vehicle) demand due to an increase in infrastructure projects. “New launches also should help Ashok Leyland to further improve sales and fill in the gaps within the portfolio,” Patil added. LCV (light commercial vehicles) and bus demand are expected to rise as Covid-19 restrictions are lifted. LKP expects the company’s profit to grow at a 106.5% CAGR over FY22-24.

    Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    27 May 2022
    The companies still winning in a tough market

    The companies still winning in a tough market

    "It's been a difficult time," CEO Sudhir Sitapati says when talking about the challenges for Godrej Consumer.

    "This turbulent period is definitely not over," Whirlpool Chairman Arvind Uppal says about the coming months.

    "We saw 12% increase in input costs at a group level in FY22. Even going forward, it remains unabated," CFO Ankush Jain of Dabur India notes.

    We are in unpredictable times - countries are dealing with food and fuel price inflation, while some like Sri Lanka are in a fiscal crisis. Back home, the Centre finally acknowledged raging commodity price inflation, imposed export limits for sugar, export duties on steel and banned international wheat shipments.

    But despite this upheaval, there was one particular sector and some companies which did surprisingly well. 

    In this week’s Analyticks we take a look at these rare winners:

    • Agrochemical exporters cash in, thanks to higher agri-commodity prices globally in Q4
    • Screener: Companies that beat inflation fears in a tough quarter, and expanded margins in Q4

    Let’s get into it.


    Agrochemical players end FY22 with strong growth and optimism

    The world has gone back to basics, focusing on agriculture output and food security. International prices of staple cereals like wheat, corn and soya bean had jumped nearly 40% YoY in March '22 triggered by Russia’s invasion of Ukraine. The prices of wheat crops alone rose over 60% YoY in March and have risen another 15% in May after  India banned wheat exports.  

    For the middle class and most businesses, the pinch of higher inflation has been sharp. But the agrochem sector is an exception, benefiting from higher agri-commodity prices in Q4FY22 as well as in FY22.

    Agrochemical players with a higher share of exports like UPL, PI Industries and Sharda Cropchem saw healthy demand and better prices for their crop protection products in Q4FY22 and full-year FY22. These particular companies manufacture formulations used in fungicides, herbicides and insecticides. 

    Will these companies see growth momentum continue in FY23?

    More demand and tight supply: Agrichem sees revenue growth in Q4

    Higher crop rates led to more staples being planted which increased demand for crop inputs like fertilisers, seeds and crop protection products. This along with tighter supplies boosted the prices of agri-inputs. Sharda Cropchem and UPL’s Q4FY22 sales realisation grew 42% and 19% YoY, respectively. However sales volumes saw muted growth. In fact, Sharda Cropchem’s volumes fell 11% YoY due to subdued demand in Europe as well as shipping and logistic issues seen across geographies. 

    North American and Latin American regions are the growth drivers for these companies. According to Crisil Research and UPL’s management, strong demand for herbicides and insecticides is coming in from Latin American countries like Brazil and Argentina. 

    The North American region (NAFTA) aided the overall topline growth for Sharda Cropchem in FY22 as the revenues rose 59% YoY to Rs 1,159 crore. UPL, on the other hand, sold higher volumes and earned better sales realisations for glufosinate, an herbicide, in the NAFTA region. 

    Coming to PI Industries, domestic revenues jumped 47% YoY to Rs 281 crore backed by higher demand for herbicides for wheat. The export revenues grew 11% YoY to Rs 1,114.2 crore and made a higher incremental contribution to the company's overall revenue growth in Q4FY22. In FY22, the export revenues grew at a much faster clip of 20% as compared to the domestic revenues (4% YoY). 

    Among the top agrochemical companies, Sharda Cropchem saw a stellar YoY growth of over 30% in its revenue and profit in Q4FY22. 

    Notably, Sharda focuses on exports and has an unusual business model. It first identifies generic molecules with expiring patents and then registers the particular formulations under its name. It then outsources the manufacturing of these formulations and undertakes only the marketing and distribution part.

    Thus, the company works on an asset-light model i.e., investment in fixed assets is minimal. It is also able to save time and capital required for research and development of new formulations. However, Sharda Cropchem still has to invest around Rs 25-40 crore on each product registration. 

    Agrochemical players to gain from the positive global agri-cycle in H1FY23

    With global prices for cereal crops rising and demand robust, Sharda Cropchem and PI industries are confident of  clocking revenue growth of 15-20% in FY23. PI Industries plans to launch four new molecules in the agrochemical exports segment and five new products for the domestic business in FY23. The company is seeing goodtraction in export-related enquiries. Analysts are also working with similar top line growth estimates (13% YoY on an average) for FY23, according to Trendlyne’s Forecaster.

    Agrochemical companies expect higher export volumes to primarily drive their revenue growth in H1FY23, provided North American weather conditions are benign. They also foresee strong domestic demand on expectations of a normal south-west monsoon in 2022. Notably, the chances of further price hikes are lower unless there is a material spike in input costs. The companies are also likely to sustain their EBITDA margin levels of 20-22% in FY23. 

    All in all, Indian agrochem companies look well placed to deliver yet another strong financial performance in FY23 amid a tough global environment. 


    Screener: Some companies successfully tamed runaway inflation in Q4

    Cost pressure is the buzzword for companies around the world. But there are some that have managed to walk through this minefield without hurting themselves.This screener shows 54 companies that saw their operating and net profit margins improve in Q4FY22. Out of these,  25 companies are part of  the Nifty 500 group.

    Commodity and speciality chemical companies like Gujarat Alkalies & Chemicals, GHCL, DCM Shriram and Gujarat Fluorochemicals feature in this screener. The sustained rise in prices of soda ash and caustic soda (up 2.5X YoY in Q4FY22) due to tight supply chains aided margin growth of companies involved in chlor-alkali and chlor-vinyl chemistry. Other than this, agrochemical companies like Anupam Rasayan and Bayer Cropscience saw their operating margins improve by more than 7 percentage points on YoY basis.

    Sugar companies like Dwarikesh Sugar Industries, Uttam Sugar Mills are also part of this list of companies as higher sales growth in the distillery segment (ethanol) resulted in margin expansion. 

    While most pharmaceutical companies missed Q4FY22 earnings estimates due to muted growth in US markets and increase in costs, some companies like Abbott India, Procter and Gamble Health and Neuland Laboratories bucked the trend. Better product mix, lower marketing and other expenses aided the margin growth of these companies.

    You can find some popular screeners here.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    27 May 2022
    Five Interesting Stocks Today

    Five Interesting Stocks Today

    1. InterGlobe Aviation (Indigo): This airline stock surged more than 7% even after it posted a loss in Q4FY22. IndiGo’s net loss rose  47% YoY to Rs 1,681 crore because of a 68% YoY surge in fuel costs to Rs 3,220.5 crore. The positive stock movement after the results was because of CEO Ronojoy Dutta’s positive outlook for the company. He said that profitability is a top priority, and also hinted at a hike in ticket prices. The CEO believes the key to profitability is managing the business well on the revenue side. It’s important to note that IndiGo has over 50% market share in India’s commercial aviation market, ending Q4 with a market share of nearly 59%.

    The company’s revenue rose in Q4FY22 by 28.9% to Rs 8,020.7 crore. But due to high aviation turbine fuel (ATF) costs the EBITDA margin fell 8.3 percentage points to 2.1%. The increase in ATF costs was much higher than the rebound in demand for air travel.

    However, it will be interesting to see how IndiGo fights to maintain its market share as Air India and SpiceJet expand flight operations. IndiGo also faces threats from new entrants like Akasa, and Jet Airways. With a volatile and bearish market, brokerage JM Financial expects the stock to remain under pressure because of increasing competition, margin pressure due to the rise in ATF prices, and Rakesh Gangwal’s decision to reduce his 36.6% stake in the company.

    1. ICICI Lombard General Insurance: This general insurance company’s stock fell over the past week after reports came in early in the week that the insurance regulator is considering a move to allow life insurers to sell health insurance products. The stock rebounded back and outperformed its industry over the past three months. This outperformance was probably due to another regulatory action that would lead to higher motor insurance premium for general and health insurers. The Ministry of Road Transport and Highways issued a notification on that will lead to an increase in third-party motor insurance premium for various categories of vehicles. The underwriting and claims head of the company considers this a positive step as premiums will rise as motor insurance premium rates were stagnant for the last two years.

    The company’s net profit in Q4FY22 fell 9.2% YoY to Rs 313 crore even though its gross direct premium income (GDPI) rose 34.2% YoY to Rs 4,666 crore. The management attributes the fall in profit to a rise in claims and underwriting losses due to the pandemic. Underwriting losses rose 128% to Rs 308.9 crore. Maximum underwriting loss was in the health segment with the retail health insurance segment’s losses growing 4.8X to Rs 50.7 crore.

    While the company faced underwriting losses in the health insurance segment, the product mix for health insurance stands unchanged at 22%, the same as FY21. Motor insurance share in the total product mix decreased to 46% in FY22 since the auto sector was on a slowdown the entire FY22.

    1. Torrent Pharmaceuticals: This pharmaceutical company’s stock rose by 10.2%, despite posting a loss of Rs 118 crore in Q4FY22 as opposed to a profit of Rs 324 crore in Q4FY21. The stock rose significantly after the company declared a final dividend of Rs 23 per share, with the total payout amounting to Rs 389.2 crore. The company’s board also recommended issuing bonus shares in the ratio of 1:1 or one share for each fully paid-up share held. The company declared a dividend despite its net profit falling 37.9% YoY to Rs 777 crore in FY22. Its cash flow from operations and trade receivables marginally increased compared to FY21. 

    The stock is also currently in the PE ‘Sell Zone’, according to Trendlyne’s Check Buy or Sell feature.. This means the stock is trading at higher PE levels than normal. The stock has remained below its current PE levels 90.7% of the time.

    The company’s revenue rose 10% YoY, driven by strong growth momentum in branded generic markets in India and Brazil. Going forward, the management guided for a 100-150bps EBITDA margin improvement in FY23 compared to 28.6% in FY22. It expects the improvement to be driven by the closure of its liquid business, cost optimization measures, and favourable pricing in the branded generics segment.

    1. National Aluminium Company (Nalco): This aluminium company’s stock closed 0.7% lower on Thursday, even though its Q4FY22 net profit rose 9.6% YoY to Rs 1,025.5 crore. The company’s profit marginally missed Trendlyne’s Forecaster estimates. The company’s revenue rose 53.8% YoY to Rs 4,340.8 crore in Q4FY22, driven by high LME (London Metal Exchange) prices, and effective raw material procurement according to the management. In FY22 the company produced 4.6 lakh tonnes of aluminium and 75.1 lakh tonnes of bauxite, its highest ever since its inception, according to the management.

    Interestingly, this stock showed on a screener which tracks big changes in FII (foreign institutional investors) holding in companies on a quarterly basis. FII holding in the company increased by 4.7 percentage points QoQ to 18%. By far, Nalco saw the biggest jump in FII holding compared to other key aluminium players such as Hindalco (+2.8 percentage points QoQ) and Vedanta (+0.7 percentage points QoQ).

    Even as aluminium prices have corrected nearly 30% from record highs during Q4FY22, the Managing Director of Nalco expects to keep up the growth momentum by increasing production and reducing raw material costs. As the company has been allocated two coal mines namely Utkal D and E, the management expects the cost of procuring coal to gradually reduce from FY24. For the coming quarters, the management expects aluminium to stabilise as it sees the gap between global production of aluminium and consumption narrowing down.

    1. Aster DM Healthcare: This healthcare service provider’s stock rose over 13% intraday after it announced its Q4FY22 results on Wednesday. Its net profit jumped 2.2X YoY to Rs 226.3 crore and revenues increased by 14.1% to Rs 2,727.8 crore. Revenue rose on the back of a 26.2% YoY growth in its India businesses. EBITDA margin rose 360 basis points YoY to 17% mainly due to a decrease in its laboratory outsourcing costs, which fell 61% YoY to Rs 54.8 crore. This stock shows up on a screener that lists companies that announced results in the last two weeks, with rising operating profit margin and YoY profit growth.

    Aster DM gets a majority (77%) of its revenues from Gulf Cooperation Council (GCC) countries and the remaining 23% from India. However, the company is focusing more on expanding its network in India as its India business is growing faster. Revenue from GCC rose 11% YoY to Rs 2,121 crore while revenue from India increased by 26.2% to Rs 607 crore in Q4FY22. This is reflected in the average occupancy rate (AOR) as well. AOR of hospitals in GCC fell 100 bps YoY to 51% in FY22 while ARR of hospitals in India rose 10 percentage points to 66%. The company plans to add up to 1,000 beds in India in FY23, indicating a 25.6% increase.

    Trendlyne's analysts identify stocks that are seeing interesting price movement, analyst calls or new developments. These are not buy recommendations.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline created a screener Stocks with a high …
    26 May 2022

    Stocks with a high percentage of retail investors

    Stocks with a high percentage of retail investors
    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    25 May 2022
    Big Misses: Many companies miss analyst profit estimates in Q4

    Big Misses: Many companies miss analyst profit estimates in Q4

    Stock markets are volatile amid signs that all is not well in the corporate world. Q4FY22 results confirmed that many businesses are struggling with rising inflation, supply pressures and worried consumers. Trendlyne’s Forecaster estimates show quite a few companies from the Nifty 500 missing Q4 net profit estimates by a large margin.

    Over 150 Nifty companies missed their adjusted net profit estimates. Trendlyne’s Forecaster shows that many companies in thepharmaceutical sector saw their actual adjusted net profit miss consensus estimates by more than 100%. Among these,Lupin’s Q4FY22 net profit missedTrendlyne’s Forecaster estimates by the widest gap of 310.7%.

    Lupin’s miss was because of a deferred taxexpense of Rs 341.9 crore.GSK Pharma is another pharma company that missed its profit estimates due to a one-time tax adjustment of Rs 202 crore.

    Most pharma companies struggled because of muted growth in US markets and an increase in costs because of freight charges, marketing expenses, and input costs. Cost pressures also led to companies in sectors likeautomobile,retailing,cement,banks, andconsumer services, to miss Trendlyne’s Forecaster profit estimates. The companies that missed Trendlyne Forecaster’s estimates by more than 100% includeTata Motors (156.9%),Trent (151.7%),Nuvoco Vistas Corporation (135.6%), andGMR Infrastructure (123.3%).

    With inflation hitting nearly 8% in April 2022, the Reserve Bank of India is hiking its rates to reduce excess liquidity in the market. This will affect the earnings of corporates in H1FY23 as demand is likely to take a hit.

    On the bright side, areport by ICICI Securities suggests that the earnings base will continue to expand over FY22-24 with more beats than misses. The brokerage expects demand and earnings to show significant improvement in sectors like real estate, banks, energy, and consumer services. As we head into the next quarter, let’s hope that the analysts' optimism turns out true in Q1FY23.

    2
    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    23 May 2022
    Five analyst stock picks this week

    Five analyst stock picks this week

    1. State Bank of India: LKP Securities maintains a ‘Buy’ rating on this public sector bank’s stock with a target price of Rs 565, indicating an upside of 22.7%. Analyst Ajit Kumar Kabi believes the bank delivered stable results led by a rise in operational revenue and improved asset quality. Kabi believes that profit growth in Q4FY22 was led by a 15.3% YoY growth in NII (net interest income), along with steady operating expenses. Kabi says “the bank witnessed better than expected advance growth (11.6% YoY & 6% QoQ) led by wholesale credit growth, and stable deposit growth (10% YoY & 5.3% QoQ) sequentially.”

    The bank’s asset quality will continue to improve in the coming quarters on the back of higher upgrades and recoveries, Kabi said Furthermore, he expects the bank’s profitability to improve in the coming quarters on the back of credit growth, normalisation of credit costs, and improving operational performance.

    1. Kajaria Ceramics: HDFC Securities maintains a ‘Buy’ call on this tile maker’s stock but reduced its target price by Rs 30 to Rs 1,420, indicating an upside of 35.6%. “We continue to like Kajaria Ceramics for its market share gain and superior margin in the tiles segment (function of its robust distribution and cost controls) and its fast expansion in the bath ware and ply businesses,” say analysts Rajesh Ravi and Keshav Lahoti. In Q4FY22, the company’s consolidated revenue grew 15.7% YoY to Rs 1,101.8 crore but profit and EBITDA fell by 24.7% YoY and 13% YoY to Rs 95.8 crore and Rs 165.9 crore, respectively. The analysts believe that the fall in EBITDA was due to higher gas prices.

    According to the analysts, the company expects volume and revenue to increase by 15-20% and 20-25% YoY respectively for FY23. The analysts also expect India’s tiles export to increase by 35% YoY as sharp spikes in gas and electricity prices in European countries have increased the competitiveness of Indian tile makers. The company “has expanded its tiles capacity by 17% in April-May 2022, bolstering its volume growth and market share gain,” the analysts said.

    1. Vinati Organics: Edelweiss reaffirmed its ‘Buy’ rating on this specialty chemical maker’s stock and increased its target price to Rs 2,300 from Rs 2,250. This indicates an upside of 11.6%. “Vinati Organics’ Q4FY22 earnings beat our expectation, with strong growth in top line primarily on account of increased volume in key products aided by market share gains for some products,” says analyst Anshul Verdia. In Q4FY22, the company’s profit grew 43% YoY to Rs 101 crore and revenue grew 74% YoY to Rs 486 crore. 

    Verdia believes that “a strong capex pipeline over the next two years indicates significant revenue generation opportunity for Vinati Organics, underpinning its aim to achieve Rs 3,000 crore in top line over the next two to three years.” He expects the company to achieve a 26% CAGR in revenue over FY22–24 on the back of increased penetration of the butyl-phenol market, robust volume growth in Acrylamide tertiary-butyl sulfonic acid and the Isobutyl Benzene business, and strong demand.

    1. Abbott India: Axis Securities maintains a ‘Buy’ call on this pharmaceutical company’s stock with a target price of Rs 20,000. This indicates an upside of 12.6%. “Abbott India reported revenue growth of 14.9% (YoY) in Q4FY22, outpacing the IPM (Indian pharma market) growth of 3.9%,” says analyst Ankush Mahajan. He adds that the revenue growth, “was majorly driven by sales improvement in key therapies such as gastrointestinal (+18.3% YoY) and hormones(+5.0% YoY).” 

    The company reported a profit of Rs 212 crore, up 38.7% YoY, and EBITDA margins improved by 465 bps YoY to 23.4%. Mahajan expects stable sales of the Duphaston brand and an increase in volume in the Thyronorm brand to help deliver revenue and profit CAGR of 11.1% and 1.3% over FY21-24. The analyst believes that revenue growth in the branded business will improve overall profitability.

    1. Century Plyboards (India): BOB Capital Markets upgrades its rating on this plywood manufacturer’s stock to ‘Buy’ from ‘Hold’ with a target price of Rs 735, indicating an upside of 37.8%. Analyst Ruchitaa Maheshwari says the company’s “long-term growth story remains intact given its strong fundamentals, impressive return ratios and healthy balance sheet”. She upgraded her rating to an attractive valuation after a 30% correction.

    The company’s growth momentum will sustain over the near-to-medium term, supported by the plywood and laminates segments, Maheshwari said she expects these segments to grow due to a pick-up in the housing sector alongside a gradual demand shift from unorganised to organised players. Maheshwari also expects better margins in the medium-density fibreboard (MDF) segment amid buoyant demand for ready-made furniture and exports. Overall, she believes the company’s EBITDA margin will expand backed by a higher MDF contribution, superior product mix, operating leverage and cost rationalisation. 

    Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline created a screener Stocks Underperforming their Industry …
    23 May 2022

    Stocks Underperforming their Industry Price Change in the Quarter

    Stocks that have underperformed their industry in Quarter Share Price Change
    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline created a screener Stocks Outperforming their Industry …
    23 May 2022

    Stocks Outperforming their Industry Price Change in the Quarter

    Stocks that have outperformed their Industry in Quarter Share Price Change
    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline created a screener Industry Underperformers Relative to …
    23 May 2022

    Industry Underperformers Relative to Nifty50 over the past Quarter

    Industries that Underperformed the Nifty50
    Copy LinkShare onShare on Share on Share on
     
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd